Fulgent Genetics (FLGT) Asset Writedowns and Impairment (2015 - 2026)

Fulgent Genetics has reported Asset Writedowns and Impairment for 12 years, with the latest figure at $2.2 million in Q2 2026.

• Quarterly Asset Writedowns and Impairment fell 71.98% year-over-year to $2.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.1 million (down 86.44% YoY) and the FY2025 annual result came in at $7.6 million, up 542.08% from the prior year.
• Asset Writedowns and Impairment grew to $2.2 million in Q2 2026 per FLGT's latest filing, from $1.2 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $11.6 million in Q1 2022 and troughed at -$11.8 million in Q4 2024.
• A 5-year average of $2.4 million and a median of $2.1 million in 2025 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2022 and 2024: Asset Writedowns and Impairment surged 990.23% in 2022, then plunged 2109.73% in 2024.
• Over 5 years, Asset Writedowns and Impairment stood at $7.3 million in 2022, then plunged by 52.7% to $3.5 million in 2023, then tumbled by 442.02% to -$11.8 million in 2024, then surged by 80.7% to -$2.3 million in 2025, then jumped by 196.58% to $2.2 million in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $2.2 million, $1.2 million, and -$2.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.